UY30416A1 - Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida - Google Patents

Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida

Info

Publication number
UY30416A1
UY30416A1 UY30416A UY30416A UY30416A1 UY 30416 A1 UY30416 A1 UY 30416A1 UY 30416 A UY30416 A UY 30416A UY 30416 A UY30416 A UY 30416A UY 30416 A1 UY30416 A1 UY 30416A1
Authority
UY
Uruguay
Prior art keywords
amino
substituted
protease inhibitors
hiv protease
benzotiazol
Prior art date
Application number
UY30416A
Other languages
English (en)
Spanish (es)
Inventor
Van T Klooster Ger Eleutherius
Baumeister Judith Eva
Dierynck Inge
Last Stefaan Julien
Boonants Paul Jozef Gabr Maria
Jonckers Tim Hugo Maria
Herman Augustinus De Kock
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of UY30416A1 publication Critical patent/UY30416A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY30416A 2006-06-23 2007-06-15 Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida UY30416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06116003 2006-06-23

Publications (1)

Publication Number Publication Date
UY30416A1 true UY30416A1 (es) 2008-01-31

Family

ID=37596252

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30416A UY30416A1 (es) 2006-06-23 2007-06-15 Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida

Country Status (30)

Country Link
US (1) US8202887B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2035432B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5232776B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101419320B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101479275B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2069A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR061619A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE544769T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2007262943B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0713487B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2653233C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2007001826A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1112971T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2035432T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA016387B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2381129T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL195381A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2841B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2009000160A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY146805A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ573286A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20080342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2035432T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2035432E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2035432T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI415851B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA96445C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY30416A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2007147884A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200810350B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
AU2011274323B2 (en) 2010-07-02 2015-08-06 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as HIV antiviral compounds
ES2634490T3 (es) 2010-07-02 2017-09-28 Gilead Sciences, Inc. Derivados de ácido napht-2-ylacetico para tratar el sida
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
BR112013027096A2 (pt) * 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
EP2788336B1 (en) 2012-04-20 2016-03-02 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287582B6 (sk) * 2001-02-14 2011-03-04 Tibotec Pharmaceuticals Ltd. 2-(Substituovaná amino)benztiazolsulfonamidová zlúčenina, spôsob jej prípravy, použitie a farmaceutická zmes s jej obsahom
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
EA008594B1 (ru) * 2002-08-02 2007-06-29 Тиботек Фармасьютикалз Лтд. 2-аминобензотиазолсульфонамидные ингибиторы протеазы вич широкого спектра действия
DE602004010291T2 (de) * 2003-09-30 2008-10-09 Tibotec Pharmaceuticals Ltd. Hcv-hemmende sulfonamide

Also Published As

Publication number Publication date
AR061619A1 (es) 2008-09-10
ATE544769T1 (de) 2012-02-15
SI2035432T1 (sl) 2012-06-29
EA200970052A1 (ru) 2009-04-28
BRPI0713487A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-11-13
KR101419320B1 (ko) 2014-07-14
JP2009541272A (ja) 2009-11-26
BRPI0713487B1 (pt) 2022-07-26
MX2009000160A (es) 2009-01-23
CA2653233A1 (en) 2007-12-27
AU2007262943A1 (en) 2007-12-27
BRPI0713487A8 (pt) 2018-01-02
CN101479275B (zh) 2012-03-07
CN101479275A (zh) 2009-07-08
AP2069A (en) 2009-12-08
UA96445C2 (ru) 2011-11-10
EP2035432A1 (en) 2009-03-18
MY146805A (en) 2012-09-28
US20090209583A1 (en) 2009-08-20
KR20090024257A (ko) 2009-03-06
PE20080342A1 (es) 2008-04-25
AU2007262943B2 (en) 2012-04-12
HK1125633A1 (en) 2009-08-14
PT2035432E (pt) 2012-04-24
NZ573286A (en) 2011-09-30
JP5232776B2 (ja) 2013-07-10
CL2007001826A1 (es) 2008-01-18
TWI415851B (zh) 2013-11-21
PL2035432T3 (pl) 2012-07-31
ZA200810350B (en) 2010-05-26
US8202887B2 (en) 2012-06-19
TW200817416A (en) 2008-04-16
ES2381129T3 (es) 2012-05-23
IL195381A0 (en) 2009-08-03
WO2007147884A1 (en) 2007-12-27
JO2841B1 (en) 2014-09-15
IL195381A (en) 2013-01-31
EA016387B1 (ru) 2012-04-30
CA2653233C (en) 2015-09-29
CY1112971T1 (el) 2016-04-13
AP2008004679A0 (en) 2008-12-31
EP2035432B1 (en) 2012-02-08
DK2035432T3 (da) 2012-05-14

Similar Documents

Publication Publication Date Title
UY30416A1 (es) Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
UY30748A1 (es) Compuesto0s novedosos
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
MX339408B (es) Composiciones farmaceuticas entericas resistentes al alcohol.
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
BR112019010622A2 (pt) composição, métodos para preparação da composição, para remover manchas e para limpeza, microcápsula, e, uso de pentano-1,2-diol.
GT200700064A (es) Agonistas de ep2
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
SV2011003786A (es) Compuestos quimicos 251
UY30610A1 (es) Moduladores de mglur5
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
CR9786A (es) Compuestos de bencimidazol-tiofeno
GT200600144A (es) 1h-quinazolin-2,4-dionas
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
HN2008001521A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
CL2011002258A1 (es) Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20191011